Latest studies
- RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
This study looks at new ways to treat type 2 diabetes by testing two medicines, Elecoglipron and Dapagliflozin, both on their own and together. Researchers want to see how well they work and if they are safe for adults with type 2 diabetes.
Type 2 Diabetes MellitusTurkey (Türkiye) - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
This study looks at a new medicine called enicepatide for people who are overweight or have obesity and also have type 2 diabetes. We want to see if it helps with weight loss and if it's safe to use.
Obesity or OverweightType 2 Diabetes MellitusTurkey (Türkiye) - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This study is testing a new medicine, Elecoglipron, for adults with type 2 diabetes and kidney problems. It compares Elecoglipron to a dummy pill (placebo) to see if it's safe and effective when taken with other usual diabetes medicines, including dapagliflozin.
Type 2 Diabetes MellitusType 2 Diabetes With Chronic Kidney DiseaseTurkey (Türkiye) - RecruitingPHASE3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
This study, called DLLEVATE, is looking at a new treatment, ZL-1310, for people with small cell lung cancer that has come back. It compares ZL-1310 to other standard treatments to see if it's safe and works well. You might be eligible if you're over 18 and have had previous treatments.
Small-cell Lung CancerTurkey (Türkiye) - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaTurkey (Türkiye) - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorTurkey (Türkiye) - Active not recruitingPHASE3
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
This study is testing a medicine called viltolarsen for boys with Duchenne muscular dystrophy who can still walk. It is an extension study for children who already completed an earlier trial. Every participant receives the medicine through a weekly drip for nearly two years to check its safety and long-term effects.
Duchenne Muscular DystrophyTurkey (Türkiye) - RecruitingPHASE3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
This study is testing a new medicine called AZD6234 for adults who are overweight or have obesity and other health issues, including some with type 2 diabetes. It aims to see if adding AZD6234 to their current weight management medicines helps them lose more weight safely.
Obesity or OverweightWeight-Related ComorbidityWith/Without Diabetes Mellitus, Type 2Turkey (Türkiye) - Recruiting
Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation
This study looks back at information from hospitals to understand serious problems that can happen during or soon after a heart procedure called ablation for fast or extra heartbeats (VT/PVC). Researchers want to find out why these problems occur and how they were managed.
Ventricular Tachycardia (VT)Premature Ventricular ComplexesTurkey (Türkiye) - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
Colorectal NeoplasmsTurkey (Türkiye) - Active not recruitingPHASE1, PHASE2
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
This study is looking at a new way to treat a type of lung cancer called non-small cell lung cancer. It combines two medicines, amivantamab and capmatinib, to see how well they work together and what the best dose is.
Carcinoma, Non-Small-Cell LungTurkey (Türkiye) - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
Biliary Tract CancerTurkey (Türkiye) - Active not recruitingPHASE3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.
Cardiovascular DiseaseTurkey (Türkiye) - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
Relapsed or Refractory Multiple MyelomaTurkey (Türkiye) - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaTurkey (Türkiye) - RecruitingPHASE3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
This study looks at a new medicine called BGB-43395 combined with letrozole for advanced breast cancer. It compares this new combination to standard treatments (other CDK4/6 inhibitors plus letrozole) for people who haven't had previous treatment for their advanced cancer.
HR+/HER2- Breast CancerTurkey (Türkiye) - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionTurkey (Türkiye) - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
Gastric Cancer, AdenocarcinomaGastroesophageal Junction AdenocarcinomaTurkey (Türkiye) - Active not recruitingPHASE3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
This study is comparing two ways of giving a medicine called amivantamab for advanced lung cancer. One is through a drip, and the other is a new injection under the skin. We want to see if the injection is easier and quicker for patients.
Advanced or Metastatic Non-small Cell Lung CancerTurkey (Türkiye) - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Turkey (Türkiye) - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerTurkey (Türkiye) - Active not recruitingPHASE3
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
This study compares a new medicine called epcoritamab with standard chemotherapy for a type of lymphoma (DLBCL) that hasn't responded to earlier treatments. It aims to see if epcoritamab is safer and more effective for patients who can't have or have already had a stem cell transplant.
Diffuse Large B-cell LymphomaTurkey (Türkiye) - Active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
Multiple MyelomaTurkey (Türkiye) - Active not recruitingPHASE3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
This study is looking at a new medicine called ravulizumab for adults with a kidney condition called IgAN. We want to see if it helps reduce kidney damage and improve kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyIgANTurkey (Türkiye) - Enrolling by invitationPHASE3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study looks at a new treatment called Selatogrel for people who have recently had a heart attack and are at risk of another. It checks if taking Selatogrel when symptoms start can help prevent a second heart attack.
Acute Myocardial InfarctionTurkey (Türkiye) - RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaTurkey (Türkiye) - RecruitingPHASE3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
This study looks at a new drug, Surovatamig, combined with rituximab, for people with previously untreated follicular lymphoma. It compares this new combination therapy with standard treatments to see if it works better and is safe.
Untreated Follicular LymphomaTurkey (Türkiye) - RecruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
Non-small Cell Lung CancerTurkey (Türkiye) - Active not recruitingPHASE3
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
This study compares two drug combinations – camizestrant with palbociclib, and anastrozole with palbociclib – for advanced breast cancer. It's for patients whose cancer has specific hormone features and hasn't yet been treated for its advanced stage. The goal is to find a better first treatment.
ER-Positive HER2-Negative Breast CancerTurkey (Türkiye) - Active not recruitingPHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
This study is looking at a new treatment called glofitamab for a type of cancer called large B-cell lymphoma. It compares this new treatment, along with other medicines, against a standard treatment for people who haven't had treatment before.
Large B-Cell LymphomaTurkey (Türkiye) - Active not recruitingPHASE2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This study looks at a new drug, efgartigimod, for adults with CIDP, a nerve condition. It aims to see how safe and effective it is over a long time when given under the skin. Some participants might also try taking the drug less often.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Turkey (Türkiye) - Active not recruitingPHASE3
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This study is looking at two new drugs, durvalumab and tremelimumab, for advanced lung cancer. It compares them to standard chemotherapy. Researchers want to see if the new combination helps people live longer and is safe as a first treatment for this type of cancer.
Non Small Cell Lung Carcinoma NSCLCTurkey (Türkiye) - RecruitingPHASE3
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study looks into a new treatment for follicular lymphoma and marginal zone lymphoma that have returned or didn't respond to previous treatments. It combines a new drug, odronextamab, with an existing one, lenalidomide, and compares it to a standard treatment.
Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)Turkey (Türkiye) - RecruitingPHASE1, PHASE2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
This study looks at a new drug, sacituzumab tirumotecan, alone or with other common treatments for advanced bowel, pancreatic, and bile duct cancers. Researchers want to see if it's safe, tolerable, and can shrink these cancers.
Colorectal CancerPancreatic Ductal AdenocarcinomaBiliary Tract CancerTurkey (Türkiye) - RecruitingPHASE3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study investigates if a new drug, vicadrostat, combined with empagliflozin, can help adults with heart failure and a weakened heart pump. Participants will take study medications for up to 3.5 years, alongside their usual care.
Heart FailureTurkey (Türkiye) - RecruitingPHASE3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.
Hepatocellular CarcinomaTurkey (Türkiye) - Active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
Multiple MyelomaTurkey (Türkiye) - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Turkey (Türkiye) - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
Prostate CancerTurkey (Türkiye) - Active not recruitingPHASE3
A Study of Zigakibart in Adults With IgA Nephropathy
This study is testing a new medicine, BION-1301, for adults with IgA Nephropathy to see if it can help their kidneys. It compares the new medicine to a dummy medicine (placebo).
IgA NephropathyImmunoglobulin A NephropathyTurkey (Türkiye) - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
This study compares a new combination medicine, BMS-986489 (BMS-986012 and Nivolumab), with a standard treatment (Atezolizumab), both given with chemotherapy. It's for people with a type of lung cancer called extensive-stage small cell lung cancer who are starting their first treatment.
Extensive-Stage Small Cell Lung CancerTurkey (Türkiye) - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesTurkey (Türkiye) - RecruitingPHASE2
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
This study looks at a new way to treat bowel cancer that has spread to the liver. Half of the patients will get a special liver treatment plus standard drugs, and the other half will get standard drugs only. It aims to see if the liver treatment is safe and effective.
Refractory Metastatic Colorectal CancerTurkey (Türkiye) - RecruitingPHASE3
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
This study looks at a new combination medicine for people with long-term kidney disease (CKD stages 3b and 4). It compares a new drug (balcinrenone/dapagliflozin) with an existing one (dapagliflozin) to see if it can slow down kidney disease and reduce heart problems, while being safe.
Renal Insufficiency, ChronicTurkey (Türkiye) - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)Turkey (Türkiye) - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
Carcinoma, Non-Small-Cell LungTurkey (Türkiye) - RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study is looking at a new combination of medicines for a certain type of advanced breast cancer. It compares a new drug, inavolisib, with existing treatments to see if it's more effective and safe for people whose cancer has a specific genetic change (PIK3CA mutation).
Breast CancerTurkey (Türkiye) - RecruitingPHASE2, PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.
Breast NeoplasmsTurkey (Türkiye) - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at two new drug combinations, amivantamab and lazertinib, compared to a standard drug, osimertinib, for people in the UK with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation).
Carcinoma, Non-Small-Cell LungTurkey (Türkiye) - RecruitingPHASE3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, pasritamig, with docetaxel to see if it helps men with advanced prostate cancer live longer without their cancer growing. It compares this combination to docetaxel alone.
Prostatic Neoplasms, Castration-ResistantTurkey (Türkiye)